Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update.

ASCO Guidelines follow the https://www.asco.org/about-asco/legal/conflict-interest-coi.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options.

ASCO指南遵循https://www.asco.org/about-asco/legal/conflict-interest-coi。ASCO提供的临床实践指南和其他指导（"指导"）并非治疗选择的全面或确定性指南。

It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment.

它旨在供临床医生自愿使用，并应与独立的专业判断一起使用。

Guidance may not be applicable to all patients, interventions, diseases or stages of diseases.

指导可能不适用于所有患者、干预措施、疾病或疾病阶段。

Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care.

指导基于相关文献的审查和分析，并不旨在作为护理标准的声明。

ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information.

ASCO不支持第三方药物、设备、服务或疗法，并不对由此信息产生的任何伤害承担责任。

See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more.

完整的免责声明请参见附录1和仅在线的附录2。

Background

To offer clinicians recommendations concerning breast cancer follow-up and surveillance after primary treatment.

为临床医生提供关于乳腺癌初次治疗后的随访和监测的建议。

Methods

ASCO convened an Expert Panel to develop recommendations based on a systematic reviewand a formal consensus process.

ASCO召集了一个专家小组，基于系统评价和正式共识过程制定了建议。

Results

One randomized controlled trial(RCT) was identified and formed the evidentiary basis for the surveillance mammography guideline recommendation.

确定了一项随机对照试验（RCT），该试验构成了监测性乳房X线摄影指南建议的证据基础。

No RCTs were identified that evaluated different follow-up approaches by risk of relapse in patients treated for early-stage breast cancer.

没有发现评估早期乳腺癌治疗患者复发风险不同随访方法的随机对照试验。

Given the dearth of evidence identified in the systematic reviewof the literature, formal modified Delphi consensus-based recommendations were generated.

鉴于在文献系统评价中确定的证据匮乏，生成了基于正式修改版Delphi共识的建议。

recommendations

The guideline offers recommendations on the role of a risk-based approach to the frequency and intensity of follow-up among patients with breast cancer in the adjuvant setting.

该指南提供了关于在辅助治疗中对乳腺癌患者随访频率和强度采用风险基础方法作用的建议。

Regular history, physical examination, and mammography are recommended for breast cancer follow-up.

推荐定期进行病史、体格检查和乳房X线摄影作为乳腺癌随访。

Either virtual or in-person visits can be offered.

可以提供虚拟或面对面的访问。

Certain patients at a high risk of cancer recurrence warrant closer surveillance, such as those patients with locally advanced disease or residual disease following neoadjuvant chemotherapy.

某些高复发风险的患者需要更密切的监测，例如那些局部晚期疾病或新辅助化疗后残留疾病的患者。

Recommendations on the use of blood-based biomarkers and supplemental imaging are provided.

提供了关于使用血液生物标志物和补充影像学的建议。

Guideline recommendations will be updated once additional evidence-based tools become available to better individualize surveillance.Additional information is available at www.ascopubs.org/topics/asco-guidelines/breast-cancer.

一旦有更多基于证据的工具可用，将更新指南建议，以更好地个性化监测。更多信息可在www.ascopubs.org/topics/asco-guidelines/breast-cancer上查看。